Progressive pulmonary fibrosis in a murine model of Hermansky-Pudlak syndrome

• Published in: Respiratory research Vol. 23; no. 1; pp. 112 - 10
• Main Authors: Abudi-Sinreich, Shachar, Bodine, Steven P, Yokoyama, Tadafumi, Tolman, Nathanial J, Tyrlik, Michal, Testa, Lauren C, Han, Chen G, Dorward, Heidi M, Wincovitch, Stephen M, Anikster, Yair, Gahl, William A, Cinar, Resat, Gochuico, Bernadette R, Malicdan, May Christine V
• Format: Journal Article
• Language: English
• Published: England BioMed Central 04.05.2022; BMC
• Subjects: Albinism; Animal models; Animals; Bleomycin; Bleomycin - toxicity; Data collection; Disease Models, Animal; Drug development; FDA approval; Fibrosis; Hemorrhagic Disorders; Hermanski-Pudlak Syndrome - chemically induced; Hermanski-Pudlak Syndrome - genetics; Hermansky-Pudlak syndrome; Histopathology; Idiopathic Pulmonary Fibrosis - pathology; Inflammation; Interstitial lung disease; Lung; Lung diseases; Mice; Pulmonary fibrosis; Rare disease; Trachea; Translational disease models; United States > US; Bleomycin; Pulmonary fibrosis; Interstitial lung disease; Rare disease; Translational disease models
• ISSN: 1465-993X; 1465-9921; 1465-993X; 1465-9921
• DOI: 10.1186/s12931-022-02002-z

HPS-1 is a genetic type of Hermansky-Pudlak syndrome (HPS) with highly penetrant pulmonary fibrosis (HPSPF), a restrictive lung disease that is similar to idiopathic pulmonary fibrosis (IPF). Hps1 (pale ear) is a naturally occurring HPS-1 mouse model that exhibits high sensitivity to bleomycin-induced pulmonary fibrosis (PF). Traditional methods of administering bleomycin as an intratracheal (IT) route to induce PF in this model often lead to severe acute lung injury and high mortality rates, complicating studies focusing on pathobiological mechanisms or exploration of therapeutic options for HPSPF. To develop a murine model of HPSPF that closely mimics the progression of human pulmonary fibrosis, we investigated the pulmonary effects of systemic delivery of bleomycin in Hps1 mice using a subcutaneous minipump and compared results to oropharyngeal delivery of bleomycin. Our study revealed that systemic delivery of bleomycin induced limited, acute inflammation that resolved. The distinct inflammatory phase preceded a slow, gradually progressive fibrogenesis that was shown to be both time-dependent and dose-dependent. The fibrosis phase exhibited characteristics that better resembles human disease with focal regions of fibrosis that were predominantly found in peribronchovascular areas and in subpleural regions; central lung areas contained relatively less fibrosis. This model provides a preclinical tool that will allow researchers to study the mechanism of pulmonary fibrosis in HPS and provide a platform for the development of therapeutics to treat HPSPF. This method can be applied on studies of IPF or other monogenic disorders that lead to pulmonary fibrosis.